Effectiveness and Feasibility of Complementary Lung-RADS Version 1.1 in Risk Stratification for pGGN in LDCT Lung Cancer Screening in a Chinese Population
Received 25 September 2019
Accepted for publication 30 December 2019
Published 9 January 2020 Volume 2020:12 Pages 189—198
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Eileen O'Reilly
Qingcheng Meng,1,* Pengfei Ren,2,* Pengrui Gao,1 Xinmin Dou,1 Xuejun Chen,1 Lanwei Guo,3 Yongping Song4
1Department of Radiology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 2Department of Molecular Pathology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 3Department of Cancer Prevention Office, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China; 4Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Yongping Song
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, People’s Republic of China
Tel/Fax +86 371 65587016
Purpose: To evaluate the effectiveness of using a modified lung imaging reporting and data system (Lung-RADS) for risk stratification of pure ground-glass nodules (pGGNs) in low-dose computed tomography (LDCT) for lung cancer (LC) screenings in China.
Patients and Methods: Eight subjects with nine pGGNs originating from a Cancer Screening Program were enrolled as training set and 32 asymptomatic subjects with 35 pGGNs were selected as validation set from November 2013 to October 2018. The complementary Lung-RADS categories were set based on the GGN-vessel relationship (GVR). The correlations between GGN-vessel relationships and pathology were evaluated, and the diagnostic value of complementary Lung-RADS version 1.1 in discriminating malignant pGGNs were analyzed.
Results: The inter-reader agreements for Lung-RADS 1.1 (intraclass correlation coefficient (ICC= 0.999) and complementary Lung-RADS 1.1 (ICC= 0.971) displayed good reliability. The combined incidence of invasive adenocarcinoma in type III and IV was more than that of benign and preinvasive diseases (30% vs 75%, P=0.013). Type II GVR between two benign (66.7%), seven preinvasive (53.8%), and six invasive (21.4%) GGN cases was statistically significant (χ2=5.415, P=0.019). GGN pathological groups and GVR had a significant correlation (r=0.584, P=0.00). Compared to Lung-RADS 1.1, complementary Lung-RADS 1.1 had better performance in the training set, with its sensitivity increased from 33.3% to 88.9%, accuracy increased from 44.4% to 88.9%, false-negative proportion (FNP) decreased from 66.7% to 11.1%, and the sensitivity to predict malignant nodules increased from 13.8% to 93.1%, accuracy increased from 28.6% to 80.0%, and FNP decreased from 86.2% to 6.9% in validation set. The detection rate of preinvasive disease and adenocarcinoma was increased from 12.5% to 90.6% and that of missed diagnosis decreased from 87.5% to 9.4% in the validation set, P=0.004.
Conclusion: Complementary Lung-RADS 1.1 is superior to Lung-RADS 1.1 and would be beneficial for LC screening of LDCT in China.
Keywords: low-dose computed tomography, lung neoplasms, lung-RADS, mass screening, ground-glass nodules
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]